Cadila Healthcare completes phase-2 trial of Hepatitis C drug for Covid-19

95% subjects in the test who received a single dose of PegiHepTM along with SOC became virus free as assessed by RT-PCR on day 14, compared to 68% of those who only received SOC

Cadila Healthcare Ltd., also known as Zydus Cadila, on Thursday announced "successful" completion of phase two clinical trial of its biological therapy Pegylated Interferon alpha-2b, ‘PegiHepTM’ on Covid-19 patients. 

 

In what now paves the way for phase three trials in India, Cadila said that the open-label, randomized, comparator controlled study was